92
Views
0
CrossRef citations to date
0
Altmetric
Clinical Features - Original research

Trunk melanomas: no survival differences between lesion sites

ORCID Icon & ORCID Icon
Pages 609-615 | Received 13 Jun 2021, Accepted 03 May 2022, Published online: 02 Jun 2022
 

ABSTRACT

Objectives

The anatomic site of primary melanoma is significantly associated with patient survival, e.g. trunk melanomas have poorer prognosis than limb melanomas. The aim of this study was to evaluate the clinicopathological factors and survival outcomes of trunk melanoma patients and to identify the differences between anatomical areas of the trunk.

Methods

A total of 491 trunk melanomas were analyzed retrospectively.

Results

The median age was 49 years. The 5-year relapse-free survival rate was 58.3% for all patients, which was 60%, 53.1%, 56.5%, 60.1%, and 66.1% for chest, abdominal, dorsal, lumbar, and gluteal melanoma patients, respectively (p = 0.8). The 5-year overall survival rate was 61.1% for all patients, which was 62.6%, 57.4%, 59.1%, 66.9%, and 72.1% for chest, abdominal, dorsal, lumbar, and gluteal melanoma patients, respectively (p = 0.3). The unfavorable pathological and clinical prognostic factors, such as sex (p = 0.0001), histology (p = 0.0001), Clark level (p = 0.0001), Breslow depth (p = 0.0001), mitotic rate (p = 0.002), ulceration (0.0001), lymphovascular invasion (p = 0.01), BRAF mutation (p = 0.01), lymph node positivity (p = 0.0001), metastasis (p = 0.0001), and relapse (p = 0.0001), were found to be associated with overall survival.

Conclusion

Trunk melanomas may be associated with aggressive pathological and poor clinical features, such as thickness, mitotic rate, ulceration, and advanced clinical stages; therefore, they predict unfavorable survival rates regardless of anatomical sites.

Disclosure statement

The authors have no relevant conflicts of interest to disclose. Peer reviewers of this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

No funding was received for the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.